Ivabradine Viatris

Ivabradine, the active ingredient in Ivabradine Viatris, is a selective If channel inhibitor presented as an oral tablet for oral use. It is used to lower heart rate in patients with chronic stable angina and in heart failure with reduced ejection fraction. GNH USA supplies Ivabradine Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradine acts on the cardiac sinus node to reduce heart rate, benefiting conditions where excessive heart rate contributes to symptoms. - Chronic stable angina: improves exercise tolerance and reduces frequency of angina episodes. - Heart failure with reduced ejection fraction: lowers heart rate, helping to improve functional capacity and reduce hospitalization risk.

Ivabradine may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects: - Bradycardia: heart rate falls below the intended therapeutic range. - Visual disturbances (phosphenes): transient luminous phenomena, especially in low‑light conditions. - Headache: mild to moderate intensity, often early in treatment. - Dizziness: may accompany reduced heart rate. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Symptomatic bradycardia requiring medical intervention. - Atrial fibrillation or other supraventricular arrhythmias. - Severe hypotension leading to syncope. - Persistent visual loss or retinal disturbances. - QT‑interval prolongation in susceptible individuals.

Before initiating therapy, clinicians should assess individual risk factors and monitor patients closely. - Heart rate monitoring: ensure resting heart rate remains above 50 bpm before dose escalation. - Severe hepatic impairment: avoid or use with extreme caution. - Sick sinus syndrome or atrioventricular block: contraindicated. - Concomitant strong CYP3A4 inhibitors: avoid due to increased plasma levels. - Pregnancy and lactation: safety not established; use only if potential benefit outweighs risk. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Ivabradine's pharmacokinetics can be altered by several co‑administered medicines.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): markedly increase ivabradine exposure. - Other bradycardic agents (beta‑blockers, digoxin): may cause excessive heart‑rate reduction. - Certain anti‑arrhythmic drugs (e.g., amiodarone): increase risk of atrial fibrillation.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil): may require dose adjustment. - CYP3A4 substrates (e.g., statins): monitor for altered plasma concentrations. - Drugs that affect electrolyte balance (e.g., diuretics): watch for additive hypotensive effects.